EBiolMed:上海交通大学提出基于信号通路的肝癌风险预测模型

2019-06-28 黄辛 中国科学报

上海交通大学生命科学技术学院俞章盛团队在肝癌风险预测研究方面取得新进展。研究基于发现的13个与肝癌生存显著相关的信号通路,构建了肝癌风险预测模型,在异质性较高的肝癌的多个数据集中取得了较高的预测精度,并与新近发表的基于深度学习框架的预测模型进行了多方面比较,表明了基于信号通路水平特征的模型在预测肿瘤风险方面具有优势。该成果近日发表在EBio Medicine上。

上海交通大学生命科学技术学院俞章盛团队在肝癌风险预测研究方面取得新进展。研究基于发现的13个与肝癌生存显著相关的信号通路,构建了肝癌风险预测模型,在异质性较高的肝癌的多个数据集中取得了较高的预测精度,并与新近发表的基于深度学习框架的预测模型进行了多方面比较,表明了基于信号通路水平特征的模型在预测肿瘤风险方面具有优势。该成果近日发表在EBio Medicine上。

肝癌是一种发病率和致死率双高的肿瘤类型,多年来在全球流行病学统计中呈上升趋势。大多数肿瘤类型研究惯常的分析方法是通过临床或者高通量数据对肿瘤患者进行分类,从而对不同临床风险类型采取更加个性化的治疗方法。

研究人员采用了同样的肝癌数据集,并通过表达数据提取对噪声更不敏感的信号通路水平的PDS作为特征,来提高预测的精度与稳定性。他们首先从3个较大的肝癌数据集中分别计算PDS,并筛选与肝癌生存风险显著相关的信号通路,进一步探究信号通路之间的影响后,得到13个与肝癌生存显著相关的通路。基于这些特征,研究团队采用与深度学习研究同样的统计模型,实现了对肝癌风险预测性能的提升,并发现了多个与肝癌生存风险相关的生物标志物。

原始出处:

Botao Fa, Chengwen Luo, Zhou Tang, et.al. Pathway-based biomarker identification with crosstalk analysis for robust prognosis prediction in hepatocellular carcinoma. EBiolmedicine June 2019 Volume 44, Pages 250–260

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2020-06-12 linagood
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2020-04-12 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2020-05-03 sjq027
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]
    2019-06-30 yuandd
  10. [GetPortalCommentsPageByObjectIdResponse(id=1997118, encodeId=c648199e1185f, content=<a href='/topic/show?id=9221645e6f' target=_blank style='color:#2F92EE;'>#EBI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6457, encryptionId=9221645e6f, topicName=EBI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1376173, createdName=linagood, createdTime=Fri Jun 12 14:15:00 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918754, encodeId=b5491918e5488, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 12 12:15:00 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767672, encodeId=7d3a1e67672e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Thu Nov 07 18:15:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061856, encodeId=d2c6206185602, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun May 03 02:15:00 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262769, encodeId=57d51262e6940, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485967, encodeId=6475148596e3a, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486041, encodeId=f1331486041a9, content=<a href='/topic/show?id=6544100912f0' target=_blank style='color:#2F92EE;'>#风险预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100912, encryptionId=6544100912f0, topicName=风险预测模型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539751, encodeId=2ac71539e51e5, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588851, encodeId=7b78158885119, content=<a href='/topic/show?id=00742438078' target=_blank style='color:#2F92EE;'>#交通#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24380, encryptionId=00742438078, topicName=交通)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84fb17623791, createdName=yuandd, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609844, encodeId=522a16098448f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jun 30 13:15:00 CST 2019, time=2019-06-30, status=1, ipAttribution=)]

相关资讯

ASCO肝癌治疗进展:O药联合伊匹木单抗 客观缓解率31%

重点纳武利尤单抗联合伊匹木单抗的客观缓解率达31%,中位缓解持续时间为17.5个月数据显示了免疫肿瘤(I-O)联合治疗方案在全球第四大致死癌症肝癌中的治疗潜力6月3日,1/2期CheckMate -040临床研究中纳武利尤单抗联合伊匹木单抗用于既往接受过索拉非尼治疗的晚期肝细胞癌患者(HCC)的首个临床研究结果在2019年美国临床肿瘤学会(ASCO)年会公布。纳武利尤单抗= 常说的O药, (欧

免疫治疗不走寻常路,肿瘤进展的肝癌患者依然有生存获益

免疫治疗尤其是PD-1/PD-L1单抗是肿瘤领域新兴的治疗方法,在多种实体瘤包括肝癌中显示出一定的疗效。免疫治疗因其独特的作用机制,疗效反应模式有别于传统治疗。在临床研究中,部分按照RECIST v1.1标准评价为疾病进展(PD)的患者,出现了非常规获益现象,即最佳疗效虽为PD,依然能从免疫治疗中获得生存获益。分享肝细胞癌免疫治疗非常规获益背后的机制。

邢宝才教授:局部联合全身系统性治疗是肝癌治疗的大势所趋

过去,原发性肝癌的主要治疗手段为外科手术。随着靶向治疗、免疫治疗药物的问世,肝癌的治疗策略逐渐从单一局部治疗向联合系统治疗转变。

演员李兆基病逝!扩散,有这些习惯的大多是肝癌高发人群!

据香港媒体报道,由于肝癌细胞扩散到肺部,抢救无效,香港演员李兆基在6月2日夜里与世长辞,享年69岁。 李兆基曾参演过《古惑仔》《纵横四海》《食神》《扫毒》等影片。由于其出身背景和外形极具草根味道,李兆基在电影中大多饰演黑道兄弟、恶霸等角色。 由于专演恶人,李兆基与黄光亮、成奎安和何家驹三人并列为“香港影圈四大恶人”。目前四人中只有黄光亮还在世。

帕博利珠单抗二线治疗肝癌虽未达统计学意义但显示临床获益

美国临床肿瘤学会(ASCO)年会在芝加哥盛大举行。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议。本届年会的主题为“Car

与索拉非尼相比,Opdivo无法显著提高肝癌患者的生存率

Bristol-Myers Squibb近日宣布,与拜耳的Nexavar(索拉非尼)相比,Opdivo(nivolumab)无法显著提高肝细胞癌(HCC)患者的总生存期(OS)。